SYRE Spyre Therapeutics reports narrower Q4 2025 pershare loss than consensus forecasts with shares edging higher in todays trading TVACU Texas management details highpotential acquisition targets in its latest quarterly earnings release VET Vermilion Q4 2025 EPS lands far below estimates shares dip 088 percent on weak results